CompletedPHASE1, PHASE2NCT01386619
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Basel, Switzerland
- Principal Investigator
- Jakob Passweg, MDUniversity Hospital, Basel, Switzerland
- Intervention
- CD3-depleted/CD56+ selected natural killer cells collected from apheresis products(biological)
- Enrollment
- 15 enrolled
- Eligibility
- All sexes
- Timeline
- 2004 – 2011
Study locations (2)
- Universitätsklinikum, Frankfurt, Germany
- University Hospital, Basel, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01386619 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07054944Tumor-Lymph Node MappingUniversity of Rochester
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC